X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Fulford India with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs TEVA PHARMA (Israel) - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 FULFORD INDIA   TEVA PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
TEVA PHARMA
Dec-13
FULFORD INDIA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs9422,840-   
Low Rs4502,467-   
Sales per share (Unadj.) Rs691.41,629.9-  
Earnings per share (Unadj.) Rs11.5101.8-  
Cash flow per share (Unadj.) Rs15.4233.6-  
Dividends per share (Unadj.) Rs2.0089.13-  
Dividend yield (eoy) %0.33.4 8.6%  
Book value per share (Unadj.) Rs380.01,810.5-  
Shares outstanding (eoy) m3.90848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.01.6 61.8%   
Avg P/E ratio x60.726.1 233.0%  
P/CF ratio (eoy) x45.311.4 398.9%  
Price / Book Value ratio x1.81.5 125.0%  
Dividend payout %17.487.5 19.9%   
Avg Mkt Cap Rs m2,7142,250,219 0.1%   
No. of employees `0000.444.9 1.0%   
Total wages/salary Rs m5050-   
Avg. sales/employee Rs Th6,073.030,752.4 19.7%   
Avg. wages/employee Rs Th1,137.40-   
Avg. net profit/employee Rs Th100.71,921.1 5.2%   
INCOME DATA
Net Sales Rs m2,6961,382,165 0.2%  
Other income Rs m1250-   
Total revenues Rs m2,8221,382,165 0.2%   
Gross profit Rs m-46378,507 -0.0%  
Depreciation Rs m15111,722 0.0%   
Interest Rs m1027,148 0.0%   
Profit before tax Rs m54239,637 0.0%   
Minority Interest Rs m01,089 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-157,308 0.0%   
Tax Rs m10-2,926 -0.3%   
Profit after tax Rs m4586,343 0.1%  
Gross profit margin %-1.727.4 -6.3%  
Effective tax rate %17.7-1.2 -1,448.1%   
Net profit margin %1.76.2 26.5%  
BALANCE SHEET DATA
Current assets Rs m1,738933,509 0.2%   
Current liabilities Rs m545814,099 0.1%   
Net working cap to sales %44.38.6 512.4%  
Current ratio x3.21.1 278.3%  
Inventory Days Days4891 53.4%  
Debtors Days Days496 4.5%  
Net fixed assets Rs m12451,445 0.0%   
Share capital Rs m393,402 1.1%   
"Free" reserves Rs m1,4430-   
Net worth Rs m1,4821,535,323 0.1%   
Long term debt Rs m0706,731 0.0%   
Total assets Rs m2,0773,158,689 0.1%  
Interest coverage x6.79.8 68.3%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.30.4 296.7%   
Return on assets %2.63.6 72.6%  
Return on equity %3.05.6 53.6%  
Return on capital %4.34.9 87.3%  
Exports to sales %00-   
Imports to sales %24.50-   
Net fx Rs m-6560-   
CASH FLOW
From Operations Rs m90220,245 0.0%  
From Investments Rs m105-78,042 -0.1%  
From Financial Activity Rs m-14-264,199 0.0%  
Net Cashflow Rs m181-121,996 -0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 68.04 Rs / USD

Compare FULFORD INDIA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare FULFORD INDIA With: CADILA HEALTHCARE  WYETH LTD  STERLING BIOTECH  ALKEM LABORATORIES  ELDER PHARMA  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 8-QTR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS